The narrative on AbbVie Inc. has been unchanging – it relies too much on top-seller Humira, is clearly behind Gilead in hepatitis C and its cancer portfolio and pipeline, while promising, aren't threatening to overtake competitors like Bristol-Myers Squibb Co. or Merck & Co. Inc. To that familiar litany, AbbVie continued its recent success July 29, reporting a sixth consecutive quarter of double-digit sales growth, paced by continued increasing sales of Humira.
The Chicago-area pharma brought in $6.432bn in global net revenue during the second quarter of 2016, up 18.0% year-over-year, with Humira (adalimumab) reporting 17.7% growth and global sales of $4.149bn
